Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20660944 | 0.89 | EGFR (0.58) | HPSENPBWR1DGAT1KCNH2EGFR | |
| SCHEMBL20661102 | 0.87 | KDM4E (0.59) | HPSENPBWR1TP53MAPTSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL29002249 | 0.80 | NPBWR1 (0.54) | NPBWR1DGAT1KCNH2 | |
| SCHEMBL6323581 | 0.79 | NR2E3 (0.55) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL15245153 | 0.78 | DGAT1 (0.54) | HPSENPBWR1DGAT1KCNH2 | |
| SCHEMBL29698856 | 0.78 | NPBWR1 (0.57) | HPSENPBWR1TP53MAPTSMN1; SMN2 | |
| SCHEMBL20001630 | 0.78 | NPBWR1 (0.57) | HPSENPBWR1TP53MAPTSMN1; SMN2 | |
| SCHEMBL15245155 | 0.78 | DGAT1 (0.56) | NPBWR1DGAT1KCNH2 | |
| SCHEMBL15245140 | 0.78 | DGAT1 (0.67) | NPBWR1DGAT1KCNH2 | |
| SCHEMBL15245237 | 0.77 | KIF11 (0.59) | NPBWR1DGAT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548867-B2 | Amido compounds as AhR modulators | IDEA YA BIOSCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210115016-A1 | AMIDO COMPOUNDS AS AhR MODULATORS | IDEAYA BIOSCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
| WO-2019018562-A1 | AMIDO COMPOUNDS AS AhR MODULATORS | IDEAYA BIOSCIENCES, INC. (US) | 2019-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115016-A1 | AMIDO COMPOUNDS AS AhR MODULATORS | AHR, ARNT, RXRB | PARP1 3872/4885HPSE 1893/4885NPBWR1 462/4885 |
| US-11548867-B2 | Amido compounds as AhR modulators | AHR, ARNT, RXRB | PARP1 3872/4885HPSE 1893/4885NPBWR1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.